Bicalutamide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Bicalutamide: From Prostate Cancer to Hypertrichosis
One-Sentence Summary
Bicalutamide is a non-steroidal androgen receptor (AR) antagonist, widely used internationally for the treatment of prostate cancer, though it holds no current Singapore (HSA) registration. The TxGNN model predicts it may be effective for Hypertrichosis, with 0 clinical trials and 1 publication currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Prostate cancer (globally established use; no Singapore registration available) |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L4 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacological knowledge, Bicalutamide is a non-steroidal androgen receptor antagonist that competitively blocks AR, preventing testosterone and dihydrotestosterone (DHT) from binding to the receptor and activating downstream signaling cascades (including PI3K/AKT and MAPK pathways) that regulate cell proliferation and differentiation.
Androgens play a well-characterized role in regulating hair follicle cycling through AR signaling. While Bicalutamide's primary indication (prostate cancer) and hypertrichosis appear anatomically unrelated, they share a common pathological driver—androgen-dependent AR activation. In certain hypertrichosis phenotypes where excess androgen stimulation is the underlying cause, blockade of AR could theoretically suppress aberrant hair follicle activation. The single available reference (PMID 35304167) is a Commentary discussing a retrospective case series in which Bicalutamide appeared to improve Minoxidil-induced hypertrichosis in female pattern hair loss patients—a population where androgen sensitivity at the follicle level is plausible.
However, a critical limitation must be acknowledged: the vast majority of hypertrichosis cases are non-androgenic in origin (congenital, drug-induced via non-AR mechanisms, or idiopathic). The mechanistic rationale for Bicalutamide is therefore confined to a narrow androgenic subtype, and the current prediction must be interpreted with this context in mind.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35304167 | 2022 | Letter/Comment | Journal of the American Academy of Dermatology | Commentary evaluating a retrospective study of 35 female pattern hair loss patients; original study reported that Bicalutamide improved Minoxidil-induced hypertrichosis, suggesting an androgen-sensitive component to this adverse effect |
Singapore Market Information
Bicalutamide is not currently registered with the Health Sciences Authority (HSA) of Singapore. No licensing records are available.
Cytotoxicity
Bicalutamide is classified as an antineoplastic agent (androgen receptor antagonist used in prostate cancer treatment).
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — Non-steroidal androgen receptor antagonist (anti-androgen) |
| Myelosuppression Risk | Low — AR antagonists do not typically cause clinically significant myelosuppression; isolated cases of anaemia reported |
| Emetogenicity Classification | Low |
| Monitoring Items | Liver function tests (LFTs) at baseline and periodically — bicalutamide is associated with hepatotoxicity risk; PSA monitoring where applicable; full blood count in patients on concomitant cytotoxic therapy |
| Handling Protection | Standard oral solid dosage form handling; dedicated cytotoxic handling precautions are generally not required for non-alkylating AR antagonists, but local pharmacy protocols should be consulted |
Safety Considerations
Please refer to the package insert for safety information.
Note: Full safety data (key warnings, contraindications, drug interactions) was not retrievable in this evidence cycle. The Singapore HSA package insert and the DrugBank monograph are the recommended sources for complete safety profiling before clinical use.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence supporting Bicalutamide's use in hypertrichosis is limited to a single Letter/Comment (L4), with no registered clinical trials. Although the androgen-AR mechanistic link is biologically plausible for a narrow androgenic hypertrichosis subtype, the absence of dedicated clinical or preclinical studies precludes advancement beyond a research hypothesis at this stage.
To proceed, the following is needed:
- Retrieve the complete Bicalutamide package insert (locally or via EMA/FDA) to close the safety data gaps (key warnings, contraindications, DDI)
- Define the target hypertrichosis subtype: confirm androgen-driven (e.g., secondary to endocrine disorder or androgen-sensitising medication) versus non-androgenic (congenital, drug-induced) forms
- Commission or identify preclinical studies characterising Bicalutamide's effect on AR-positive hair follicle models
- Assess feasibility of a pilot investigator-initiated study in patients with confirmed androgen-sensitive hypertrichosis
- Register Bicalutamide with HSA or identify a compassionate use pathway before any clinical application in Singapore
⚠ Research Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application. This analysis was generated on 2026-06-01 based on data available at that time.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.